File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer
  • Basic View
  • Metadata View
  • XML View
TitleCapecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer
 
AuthorsChua, D1 2
Wei, WI1
Sham, JST1
Au, GKH1
 
KeywordsCapecitabine
Hand-foot syndrome
Nasopharyngeal carcinoma
Palliative chemotherapy
 
Issue Date2008
 
PublisherOxford University Press. The Journal's web site is located at http://jjco.oxfordjournals.org/
 
CitationJapanese Journal Of Clinical Oncology, 2008, v. 38 n. 4, p. 244-249 [How to Cite?]
DOI: http://dx.doi.org/10.1093/jjco/hyn022
 
Abstractbackground: Capecitabine monotherapy had activity in recurrent/metastatic nasopharyngeal carcinoma (NPC) as demonstrated previously in a small pilot study. We conducted a retrospective review of patients who received capecitabine for recurrent and metastatic NPC to further evaluate its clinical benefits. Methods: Forty-nine patients with recurrent and metastatic NPC received capecitabine at a dose of 1-1.25 G/m2 twice daily for 14 days in 3-week cycles. Disease sites were locoregional in 29%, distant in 45% and locoregional plus distant in 26%. All except one had prior platinum-based chemotherapy for relapse or as adjunctive treatment. Median follow-up was 10 months (range: 3-41). Results: Treatment was generally well tolerated. Hand-foot syndrome was common and occurred in 86%; (25% Grade 3). Grade 3 hematological toxicity occurred in 6%. Partial response rate was 31% (95% CI: 18%, 44%) and complete response rate was 6% (95% CI: 0%, 13%), for an overall response rate of 37% (95% CI: 23%, 50%). Median time-to-progression was 5 months and median survival was 14 months. One- and two-year survival rates were 54 and 26%, respectively. Significantly better survival was observed in patients treated for locoregional recurrence and those with severe hand-foot syndrome. Conclusions: Capecitabine has single agent activity in NPC and severe hand-foot syndrome predicts favorable outcome. Based on our experience, capecitabine monotherapy should be considered in patients with recurrent/ metastatic NPC. © The Author (2008). Published by Oxford University Press. All rights reserved.
 
ISSN0368-2811
2012 Impact Factor: 1.898
2012 SCImago Journal Rankings: 0.789
 
DOIhttp://dx.doi.org/10.1093/jjco/hyn022
 
ISI Accession Number IDWOS:000255439200002
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorChua, D
 
dc.contributor.authorWei, WI
 
dc.contributor.authorSham, JST
 
dc.contributor.authorAu, GKH
 
dc.date.accessioned2010-09-06T08:41:39Z
 
dc.date.available2010-09-06T08:41:39Z
 
dc.date.issued2008
 
dc.description.abstractbackground: Capecitabine monotherapy had activity in recurrent/metastatic nasopharyngeal carcinoma (NPC) as demonstrated previously in a small pilot study. We conducted a retrospective review of patients who received capecitabine for recurrent and metastatic NPC to further evaluate its clinical benefits. Methods: Forty-nine patients with recurrent and metastatic NPC received capecitabine at a dose of 1-1.25 G/m2 twice daily for 14 days in 3-week cycles. Disease sites were locoregional in 29%, distant in 45% and locoregional plus distant in 26%. All except one had prior platinum-based chemotherapy for relapse or as adjunctive treatment. Median follow-up was 10 months (range: 3-41). Results: Treatment was generally well tolerated. Hand-foot syndrome was common and occurred in 86%; (25% Grade 3). Grade 3 hematological toxicity occurred in 6%. Partial response rate was 31% (95% CI: 18%, 44%) and complete response rate was 6% (95% CI: 0%, 13%), for an overall response rate of 37% (95% CI: 23%, 50%). Median time-to-progression was 5 months and median survival was 14 months. One- and two-year survival rates were 54 and 26%, respectively. Significantly better survival was observed in patients treated for locoregional recurrence and those with severe hand-foot syndrome. Conclusions: Capecitabine has single agent activity in NPC and severe hand-foot syndrome predicts favorable outcome. Based on our experience, capecitabine monotherapy should be considered in patients with recurrent/ metastatic NPC. © The Author (2008). Published by Oxford University Press. All rights reserved.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationJapanese Journal Of Clinical Oncology, 2008, v. 38 n. 4, p. 244-249 [How to Cite?]
DOI: http://dx.doi.org/10.1093/jjco/hyn022
 
dc.identifier.doihttp://dx.doi.org/10.1093/jjco/hyn022
 
dc.identifier.epage249
 
dc.identifier.hkuros141513
 
dc.identifier.isiWOS:000255439200002
 
dc.identifier.issn0368-2811
2012 Impact Factor: 1.898
2012 SCImago Journal Rankings: 0.789
 
dc.identifier.issue4
 
dc.identifier.openurl
 
dc.identifier.pmid18407933
 
dc.identifier.scopuseid_2-s2.0-42549151234
 
dc.identifier.spage244
 
dc.identifier.urihttp://hdl.handle.net/10722/83489
 
dc.identifier.volume38
 
dc.languageeng
 
dc.publisherOxford University Press. The Journal's web site is located at http://jjco.oxfordjournals.org/
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofJapanese Journal of Clinical Oncology
 
dc.relation.referencesReferences in Scopus
 
dc.rightsJapanese Journal of Clinical Oncology. Copyright © Oxford University Press.
 
dc.subjectCapecitabine
 
dc.subjectHand-foot syndrome
 
dc.subjectNasopharyngeal carcinoma
 
dc.subjectPalliative chemotherapy
 
dc.titleCapecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Chua, D</contributor.author>
<contributor.author>Wei, WI</contributor.author>
<contributor.author>Sham, JST</contributor.author>
<contributor.author>Au, GKH</contributor.author>
<date.accessioned>2010-09-06T08:41:39Z</date.accessioned>
<date.available>2010-09-06T08:41:39Z</date.available>
<date.issued>2008</date.issued>
<identifier.citation>Japanese Journal Of Clinical Oncology, 2008, v. 38 n. 4, p. 244-249</identifier.citation>
<identifier.issn>0368-2811</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/83489</identifier.uri>
<description.abstract>background: Capecitabine monotherapy had activity in recurrent/metastatic nasopharyngeal carcinoma (NPC) as demonstrated previously in a small pilot study. We conducted a retrospective review of patients who received capecitabine for recurrent and metastatic NPC to further evaluate its clinical benefits. Methods: Forty-nine patients with recurrent and metastatic NPC received capecitabine at a dose of 1-1.25 G/m2 twice daily for 14 days in 3-week cycles. Disease sites were locoregional in 29%, distant in 45% and locoregional plus distant in 26%. All except one had prior platinum-based chemotherapy for relapse or as adjunctive treatment. Median follow-up was 10 months (range: 3-41). Results: Treatment was generally well tolerated. Hand-foot syndrome was common and occurred in 86%; (25% Grade 3). Grade 3 hematological toxicity occurred in 6%. Partial response rate was 31% (95% CI: 18%, 44%) and complete response rate was 6% (95% CI: 0%, 13%), for an overall response rate of 37% (95% CI: 23%, 50%). Median time-to-progression was 5 months and median survival was 14 months. One- and two-year survival rates were 54 and 26%, respectively. Significantly better survival was observed in patients treated for locoregional recurrence and those with severe hand-foot syndrome. Conclusions: Capecitabine has single agent activity in NPC and severe hand-foot syndrome predicts favorable outcome. Based on our experience, capecitabine monotherapy should be considered in patients with recurrent/ metastatic NPC. &#169; The Author (2008). Published by Oxford University Press. All rights reserved.</description.abstract>
<language>eng</language>
<publisher>Oxford University Press. The Journal&apos;s web site is located at http://jjco.oxfordjournals.org/</publisher>
<relation.ispartof>Japanese Journal of Clinical Oncology</relation.ispartof>
<rights>Japanese Journal of Clinical Oncology. Copyright &#169; Oxford University Press.</rights>
<subject>Capecitabine</subject>
<subject>Hand-foot syndrome</subject>
<subject>Nasopharyngeal carcinoma</subject>
<subject>Palliative chemotherapy</subject>
<title>Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0368-2811&amp;volume=38&amp;spage=244&amp;epage=9&amp;date=2008&amp;atitle=Capecitabine+monotherapy+for+recurrent+and+metastatic+nasopharyngeal+cancer.</identifier.openurl>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1093/jjco/hyn022</identifier.doi>
<identifier.pmid>18407933</identifier.pmid>
<identifier.scopus>eid_2-s2.0-42549151234</identifier.scopus>
<identifier.hkuros>141513</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-42549151234&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>38</identifier.volume>
<identifier.issue>4</identifier.issue>
<identifier.spage>244</identifier.spage>
<identifier.epage>249</identifier.epage>
<identifier.isi>WOS:000255439200002</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong
  2. Queen Mary Hospital Hong Kong